At Bowen, we offer a comprehensive range of contract research services, specializing in the discovery of recombinant proteins and antibodies.
- Advanced Immunization Methods: Targeted immunization near lymph nodes.
- Antigen Selection: Proteins, peptides, DNA, mRNA, and cells.
- High-Efficiency Adjuvants: Water-soluble adjuvants for improved immune responses with reduced side effects.
- Sequence Identification & Validation: 1) Target cell FACS selection/sequencing, 2) phage display panning.
- Developability Assessments: Expression, solubility, specificity, and stability evaluations.
- Analytical Assays: Comprehensive tests, including ELISA, HPLC, FPLC, and pathology analysis.
Bowen is at the forefront of developing Toll-like receptor (TLR) agonists, designed to stimulate immune responses for cancer and infectious diseases.
- Advanced Immunization Methods: Targeted immunization near lymph nodes.
- Intra-Tumor Injection: Developing vaccines for solid tumors such as skin, prostate, breast, thyroid, and cervical cancers.
Bowen offers small animal studies at the AAALAC-accredited UMASS Animal Center.
Additionally, Bowen has partnerships with CFDA-accredited institutions in China to conduct full-scale preclinical evaluations, ensuring comprehensive drug development support.
Bowen Therapeutics is equipped to conduct investigator-initiated trials (IITs) at UMASS Worcester. We collaborate with hospitals in both the U.S. and China to assess biological efficacy and safety.
Bowen also provides regulatory services, working closely with regulatory experts to guide biopharmaceutical, nutraceutical, cosmetics, and diagnostics industries through FDA and CFDA approval processes.